c-MYC: more than just a matter of life and death.
Deregulated expression of c-MYC occurs in a broad range of human cancers and is often associated with poor prognosis, indicating a key role for this oncogene in tumour progression. However, as established human tumours often bear multiple genetic lesions, it is difficult to determine whether c-MYC is instrumental in the initiation/progression of the tumour, or indeed whether inactivating c-MYC would lead to tumour regression. Regulatable transgenic mouse models of oncogenesis have shed light on these issues and provide hope for effective cancer therapies.
D000818:Animals; D017209:Apoptosis; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D002843:Chromatin / Q000378:metabolism; D019281:Dimerization; D016193:G1 Phase; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D010641:Phenotype; D017434:Protein Structure, Tertiary; D016271:Proto-Oncogene Proteins c-myc / Q000737:chemistry / Q000378:metabolism* / Q000502:physiology*; D016196:S Phase; D014157:Transcription Factors / Q000378:metabolism
D002843:Chromatin; D016271:Proto-Oncogene Proteins c-myc; D014157:Transcription Factors